Revenue: As of FY2026 Q1, the actual value is USD 667.43 K.EPS: As of FY2026 Q1, the actual value is USD -0.12.EBIT: As of FY2026 Q1, the actual value is USD -1.413 M.<h3>Segment Revenue</h3><ul><li>Pocono Pharmaceuticals: Revenue for the three months ended April 30, 2025, was $667,432, compared to $408,532 for the same period in 2024, indicating an increase due to additional equipment and expected demand growth.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: Pocono Pharmaceuticals reported a gross profit of $251,981 for the three months ended April 30, 2025, compared to $164,786 for the same period in 2024.</li><li>Operating Expenses: Total operating expenses for the three months ended April 30, 2025, were $1,665,478, compared to $2,054,263 for the same period in 2024. This includes selling, general, and administrative expenses and research and development costs.</li><li>Net Loss: The company reported a net loss of $1,388,869 for the three months ended April 30, 2025, compared to a net loss of $1,898,077 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: The company used $1,336,972 in cash for operating activities during the three months ended April 30, 2025.</li><li>Free Cash Flow: Not explicitly stated, but the net change in cash was -$1,347,622 for the three months ended April 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company is focused on developing its AVERSA abuse deterrent transdermal technology, with plans to expand its product pipeline to include AVERSA Buprenorphine and AVERSA Methylphenidate. The company has a commercial development and clinical supply agreement with Kindeva Drug Delivery for AVERSA Fentanyl.</li><li>Priority: The company emphasizes the development of its AVERSA technology and the potential for market expansion through new product lines, with a focus on achieving FDA approval for its lead product, AVERSA Fentanyl.</li></ul>

NUTRIBAND INC C/WTS (TO PUR COM) | 10-Q: FY2026 Q1 Revenue: USD 667.43 K